Outcomes and Genomic Landscape of Patients Treated with Re-Irradiation for Recurrent Head and Neck Cancer Using Pencil Beam Scanning Proton Therapy: The Maryland Proton Treatment Center Experience
R.F. Krc,W. Mendes,J.K. Molitoris,M. Ferris,Y. Song,A.C. Shetty,R. Mehra,J. Papadimitriou,K. Hatten,R. Taylor,J. Wolf,K. Sun,S.M. Bentzen,W.F. Regine,P.T. Tran,M.E. Witek
DOI: https://doi.org/10.1016/j.ijrobp.2024.01.086
IF: 8.013
2024-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s) Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) after prior HNC RT is clinically challenging given prior radiation of nearby organs at risk (OARs). We describe clinical outcomes and toxicity of pencil beam scanning proton therapy (PBS-PT) for recurrent HNC, and report genomic alterations associated with patterns of failure to improve clinical decision making. Materials/Methods We performed a retrospective analysis of rHNC patients treated at a single institution with PBS-PT. Baseline demographic, disease and treatment characteristics were recorded. Clinical outcomes were estimated using the Kaplan-Meier method. Univariable (UVA) and multivariable analyses (MVA) were performed to assess patient, disease, and treatment related factors. Acute and late grade 3+ toxicities were assessed per CTCAE v5.0. Next generation sequencing (NGS) and genomic analyses were performed on available samples. Results Eighty-nine patients treated with PBS-PT for rHNC between 2016 and 2022 with a median follow-up of 12 months (range 0-71) were included. The 1- and 2-year local control rates were 80.8% (95% CI: 70.8-90.8) and 66.2% (95% CI: 50.7-81.7) and 1- and 2-year distant metastasis free survival (DMFS) were 41.0% (95% CI: 30.0-52.0) and 26.3% (95% CI: 15.7-36.9). Median overall survival (OS) was 13 months (95% CI: 9.3-16.7). On UVA and MVA, smaller gross tumor volume was associated with improved OS (HR 1.002, p=.004), DMFS (HR 1.002, p=0.004) and progression free survival (PFS) (HR 1.002, p=0.014). There were 35 late grade 3 or higher toxicity events (30.3%), including one patient that suffered late grade 5 osteoradionecrosis resulting in sepsis. Patients with higher candidate gene specific mutation burden (genes with odds-ratio >2, p<0.05) had inferior PFS. In addition, TP53, NOTCH4 and ARID1B mutations were associated with inferior DMFS (OR>2, p<0.05). Of the top 28 highly mutated genes (mutated in ≥ 3 samples in either group, odd ratio>2), TP53 was the most frequently mutated gene in DMFS alive group with Met(78%), followed by NOTCH4(52%), ARID1B (33%). please see table table1b. Conclusion Pencil beam scanning proton therapy re-irradiation is effective at achieving local control for recurrent head and neck cancer and is associated with a favorable toxicity profile. Distant metastases comprise the major failure pattern for this patient population and are associated with TP53, NOTCH4, and ARID1B somatic mutations. Validation of these findings may provide rationale for the inclusion of genomic alterations in the clinical decision process.
oncology,radiology, nuclear medicine & medical imaging